We are studying whether imlifidase, combined with standard care, can improve outcomes for patients with severe ANCA-associated vasculitis and pulmonary hemorrhage. The trial will also assess its safety and effects on health markers.
Health conditions and diseases that the clinical trial is designed to study and treat.
ANCA-associated vasculitis is a group of autoimmune diseases that cause inflammation of blood vessels, leading to damage in various organs, particularly the lungs and kidneys. It can result in severe symptoms like respiratory distress and kidney failure.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.